BRPI0821069A2 - Derivados de oxadiazol ativos em 1-fosfa de esfingosina (s1p) - Google Patents
Derivados de oxadiazol ativos em 1-fosfa de esfingosina (s1p)Info
- Publication number
- BRPI0821069A2 BRPI0821069A2 BRPI0821069-1A BRPI0821069A BRPI0821069A2 BR PI0821069 A2 BRPI0821069 A2 BR PI0821069A2 BR PI0821069 A BRPI0821069 A BR PI0821069A BR PI0821069 A2 BRPI0821069 A2 BR PI0821069A2
- Authority
- BR
- Brazil
- Prior art keywords
- sphingosine
- phosphate
- oxadiazole derivatives
- derivatives active
- active
- Prior art date
Links
- 150000004866 oxadiazoles Chemical class 0.000 title 1
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0725101.0A GB0725101D0 (en) | 2007-12-21 | 2007-12-21 | Compounds |
| PCT/EP2008/067963 WO2009080724A1 (en) | 2007-12-21 | 2008-12-19 | Oxadiazole derivatives active on sphingosine-1-phosphate (s1p) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0821069A2 true BRPI0821069A2 (pt) | 2015-06-16 |
Family
ID=39048651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0821069-1A BRPI0821069A2 (pt) | 2007-12-21 | 2008-12-19 | Derivados de oxadiazol ativos em 1-fosfa de esfingosina (s1p) |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8278324B2 (pt) |
| EP (2) | EP2225233B1 (pt) |
| JP (1) | JP2011506568A (pt) |
| KR (1) | KR20100108568A (pt) |
| CN (1) | CN101945864A (pt) |
| AU (1) | AU2008339987B2 (pt) |
| BR (1) | BRPI0821069A2 (pt) |
| CA (1) | CA2710067A1 (pt) |
| CO (1) | CO6290688A2 (pt) |
| CR (1) | CR11578A (pt) |
| DK (1) | DK2225233T3 (pt) |
| DO (1) | DOP2010000187A (pt) |
| EA (1) | EA018637B1 (pt) |
| ES (1) | ES2431795T3 (pt) |
| GB (1) | GB0725101D0 (pt) |
| HR (1) | HRP20131053T1 (pt) |
| IL (1) | IL206278A0 (pt) |
| MA (1) | MA31922B1 (pt) |
| NZ (1) | NZ585994A (pt) |
| PL (1) | PL2225233T3 (pt) |
| PT (1) | PT2225233E (pt) |
| UA (1) | UA102539C2 (pt) |
| WO (1) | WO2009080724A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0725101D0 (en) * | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| PE20091339A1 (es) | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
| GB0725105D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| GB0807910D0 (en) | 2008-04-30 | 2008-06-04 | Glaxo Group Ltd | Compounds |
| GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
| EP2481740B1 (en) * | 2011-01-26 | 2015-11-04 | DemeRx, Inc. | Methods and compositions for preparing noribogaine from voacangine |
| WO2014129796A1 (en) | 2013-02-20 | 2014-08-28 | Lg Life Sciences Ltd. | Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent |
| WO2018231745A1 (en) * | 2017-06-14 | 2018-12-20 | Trevena, Inc. | Compounds for modulating s1p1 activity and methods of using the same |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1180026A (ja) * | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| JP2005533058A (ja) * | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Edg受容体アゴニストとしての1−((5−アリール−1,2,4−オキサジアゾール−3−イル)ベンジル)アゼチジン−3−カルボキシラートおよび1−((5−アリール−1,2,4−オキサジアゾール−3−イル)ベンジル)ピロリジン−3−カルボキシラート |
| MXPA05012461A (es) * | 2003-05-19 | 2006-02-22 | Irm Llc | Compuestos y composiciones inmunosupresores. |
| ATE537825T1 (de) * | 2003-05-19 | 2012-01-15 | Irm Llc | Immunosuppressive verbindungen und zusammensetzungen |
| WO2004113330A1 (en) | 2003-05-19 | 2004-12-29 | Irm Llc | Immunosuppressant compounds and compositions |
| MY150088A (en) * | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| AU2004299456B2 (en) * | 2003-12-17 | 2010-10-07 | Merck Sharp & Dohme Corp. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
| WO2006001463A1 (ja) | 2004-06-23 | 2006-01-05 | Ono Pharmaceutical Co., Ltd. | S1p受容体結合能を有する化合物およびその用途 |
| AU2005299851B2 (en) * | 2004-10-22 | 2011-03-17 | Merck Sharp & Dohme Corp. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists |
| ES2519346T3 (es) * | 2004-12-13 | 2014-11-06 | Ono Pharmaceutical Co., Ltd. | Derivado de ácido azetidinacarboxílico y uso medicinal del mismo |
| RU2404178C2 (ru) | 2005-03-23 | 2010-11-20 | Актелион Фармасьютиклз Лтд | Новые производные тиофена в качестве агонистов рецептора сфингозин-1-фосфата-1 |
| CN101203512A (zh) * | 2005-04-22 | 2008-06-18 | 第一三共株式会社 | 杂环化合物 |
| WO2006131336A1 (en) | 2005-06-08 | 2006-12-14 | Novartis Ag | POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS |
| MX2008002540A (es) | 2005-08-23 | 2008-03-14 | Irm Llc | Compuestos inmunosupresores y composiciones. |
| WO2007116866A1 (ja) * | 2006-04-03 | 2007-10-18 | Astellas Pharma Inc. | ヘテロ化合物 |
| WO2008064337A2 (en) * | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
| GB0725102D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| PE20091339A1 (es) | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
| GB0725105D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| GB0725101D0 (en) * | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| GB0725104D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
-
2007
- 2007-12-21 GB GBGB0725101.0A patent/GB0725101D0/en not_active Ceased
-
2008
- 2008-12-19 BR BRPI0821069-1A patent/BRPI0821069A2/pt not_active IP Right Cessation
- 2008-12-19 CA CA2710067A patent/CA2710067A1/en not_active Abandoned
- 2008-12-19 JP JP2010538740A patent/JP2011506568A/ja not_active Ceased
- 2008-12-19 EP EP08863529.7A patent/EP2225233B1/en active Active
- 2008-12-19 KR KR1020107016169A patent/KR20100108568A/ko not_active Ceased
- 2008-12-19 EP EP13182453.4A patent/EP2746254A3/en not_active Withdrawn
- 2008-12-19 CN CN2008801273526A patent/CN101945864A/zh active Pending
- 2008-12-19 ES ES08863529T patent/ES2431795T3/es active Active
- 2008-12-19 EA EA201070781A patent/EA018637B1/ru not_active IP Right Cessation
- 2008-12-19 PT PT88635297T patent/PT2225233E/pt unknown
- 2008-12-19 HR HRP20131053AT patent/HRP20131053T1/hr unknown
- 2008-12-19 WO PCT/EP2008/067963 patent/WO2009080724A1/en not_active Ceased
- 2008-12-19 PL PL08863529T patent/PL2225233T3/pl unknown
- 2008-12-19 DK DK08863529.7T patent/DK2225233T3/da active
- 2008-12-19 US US12/747,191 patent/US8278324B2/en not_active Expired - Fee Related
- 2008-12-19 NZ NZ585994A patent/NZ585994A/en not_active IP Right Cessation
- 2008-12-19 UA UAA201009200A patent/UA102539C2/ru unknown
- 2008-12-19 AU AU2008339987A patent/AU2008339987B2/en not_active Ceased
-
2010
- 2010-02-24 US US12/711,318 patent/US20100152235A1/en not_active Abandoned
- 2010-06-10 IL IL206278A patent/IL206278A0/en unknown
- 2010-06-16 MA MA32924A patent/MA31922B1/fr unknown
- 2010-06-18 DO DO2010000187A patent/DOP2010000187A/es unknown
- 2010-06-21 CO CO10074471A patent/CO6290688A2/es active IP Right Grant
- 2010-07-21 CR CR11578A patent/CR11578A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MA31922B1 (fr) | 2010-12-01 |
| EP2746254A2 (en) | 2014-06-25 |
| ES2431795T3 (es) | 2013-11-28 |
| EP2746254A3 (en) | 2014-10-15 |
| US8278324B2 (en) | 2012-10-02 |
| AU2008339987A1 (en) | 2009-07-02 |
| EP2225233A1 (en) | 2010-09-08 |
| DOP2010000187A (es) | 2010-08-15 |
| US20100152235A1 (en) | 2010-06-17 |
| DK2225233T3 (da) | 2013-10-14 |
| EA018637B1 (ru) | 2013-09-30 |
| JP2011506568A (ja) | 2011-03-03 |
| EA201070781A1 (ru) | 2010-12-30 |
| EP2225233B1 (en) | 2013-09-04 |
| IL206278A0 (en) | 2010-12-30 |
| HRP20131053T1 (hr) | 2013-12-06 |
| CO6290688A2 (es) | 2011-06-20 |
| AU2008339987B2 (en) | 2013-03-21 |
| GB0725101D0 (en) | 2008-01-30 |
| PL2225233T3 (pl) | 2014-01-31 |
| CR11578A (es) | 2010-09-23 |
| US20100273827A1 (en) | 2010-10-28 |
| NZ585994A (en) | 2012-02-24 |
| KR20100108568A (ko) | 2010-10-07 |
| CN101945864A (zh) | 2011-01-12 |
| UA102539C2 (ru) | 2013-07-25 |
| CA2710067A1 (en) | 2009-07-02 |
| PT2225233E (pt) | 2013-11-22 |
| WO2009080724A1 (en) | 2009-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0820131A2 (pt) | Derivados de oxadiazol ativos em esfingosina-1-fosfato (s1p) | |
| CY2020036I2 (el) | Δοσολογικο σχημα για εναν αγωνιστη του υποδοχεα s1p | |
| BRPI0821069A2 (pt) | Derivados de oxadiazol ativos em 1-fosfa de esfingosina (s1p) | |
| IL200870A0 (en) | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists | |
| LTC2379069I2 (lt) | S1p receptoriaus agonisto dozavimas | |
| BRPI0818457A2 (pt) | Derivados de oxadiazol | |
| BRPI1009274A2 (pt) | arquitetura de memória virtual sem uniformidade para máquinas virtuais | |
| EP2364089A4 (en) | Heterocyclic sphingosine-1-phosphate analogues | |
| BRPI0918935A2 (pt) | compostos amida úteis em terapia | |
| BRPI0923178A2 (pt) | derivados heterocíclicos de oxadiazol fundidos úteis para o tratamento de esclerose múltipla | |
| DE502008002369D1 (de) | Kühlmittelzuführung | |
| NO20080700L (no) | Opplagringssystem for rotor i roterende maskiner | |
| BR112013013648A2 (pt) | derivados de fenil oxadiazol como moduladores de receptor de esfingosina-1-fosfato(s1p) | |
| IL224071B (en) | 5-(biphenyl-r-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate (s1p) receptors | |
| EP1981154A4 (en) | DYNAMOELECTRIC MACHINE | |
| BRPI0815299A2 (pt) | estabilizantes fosfito para composto ionoméricos de poliester | |
| EP2045896A4 (en) | DYNAMOELECTRIC MACHINE | |
| EP1997881A4 (en) | TUBERCULOSIS VACCINE | |
| BR112013013644A2 (pt) | derivados de oxadiazol como moduladores dos receptores de esfingosina 1-fosfato (s1p) | |
| ES1069167Y (es) | Maquina para tatuar | |
| FI20075394L (fi) | Polttoaineen syöttöjärjestelmän polttoainevarasto | |
| GB0722340D0 (en) | Sphingosine-1-phosphate (S1P) receptor compounds | |
| ZA200906256B (en) | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists | |
| HK1142071A (en) | Oxadiazole derivatives active on sphingosine-1-phosphate (s1p) | |
| ES1067730Y (es) | Dispositivo autoblocante para persiana |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |